Ticker

DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer's global drug development expertise with Henry Ford Health's comprehensive clinical research program and its deep connection to the communities it serves. “Clinical trials are often the first opportunity…

Bayer Aktiengesellschaft remains undervalued despite a strong 18-month rally and ongoing operational improvements. I see upside potential supported by improving EBIT, robust pipeline assets, and technical breakout, though litigation and high debt persist. Litigation settlements and negative free cash flow weigh on the balance sheet, but recent Apollo investment and restructuring efforts provide some relief.

The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.

Bayer said on Friday it had secured €3 ​billion ($3.4 billion) in equity from ‌Apollo-managed funds in a deal tied to its long-acting reversible contraceptives, or LARC, business, ​aiming to bolster its capital ​structure while preserving control.

June 30 (Reuters) - Bayer asked ​Washington to impose duties on glyphosate, the chemical used in the company's weedkiller Roundup, ‌imported from China, saying it was being sold at artificially low prices.